Moonlight begins SURVEYOR Phase I trial for peanut allergy

▤ Summary

Moonlight Therapeutics has started the SURVEYOR Phase I trial for MOON101, an investigational immunotherapy for peanut allergy. The study will enroll up to 40 participants ages four to 55 across U.S. clinical sites and will evaluate safety, tolerability, and immune response. MOON101 uses a minimally invasive microneedle skin stamp designed to deliver small doses of peanut extract with low burden and potential at-home use. The trial marks the company’s move from preclinical research into human testing and follows FDA review of the IND application, with additional support from the National Institute of Allergy and Infectious Diseases.

▦ Linked Companies